Andrew Klein, MD
Interventional Cardiology · Atlanta, GANPI 1366482424
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.3%.
Across 208 payments — averaging $56.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$2K
- Endovascular Engineering Inc.$2K
- Boston Scientific$2K
- Datascope Corp.$1K
- Novartis$950
- Angiodynamics, Inc.$669
- plus $3K from 19 others
Across 205 payments — averaging $2813.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$351K
- Abbott$60K
- Angiodynamics, Inc.$46K
- Boston Scientific$45K
- Endovascular Engineering Inc.$40K
- Surmodics, Inc.$21K
- plus $12K from 1 others
What the payments were for
- Speaking & faculty fees$1,20010%
- Travel & lodging$3,50530%
- Food & beverage$6,98660%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 19 | $2,257 |
| Endovascular Engineering Inc. | 7 | $1,920 |
| Boston Scientific | 26 | $1,742 |
| Datascope Corp. | 1 | $1,200 |
| Novartis | 52 | $950 |
| Angiodynamics, Inc. | 6 | $669 |
| Johnson & Johnson | 37 | $667 |
| Medtronic | 11 | $489 |
| Abiomed | 4 | $405 |
| Shockwave Medical, Inc | 9 | $329 |
| Edwards Lifesciences | 4 | $160 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $149 |
| Chiesi USA, Inc. | 1 | $133 |
| EKOS Corporation | 1 | $112 |
| Amgen | 5 | $96 |
| Amarin Pharma, Inc. | 5 | $93 |
| E.r. Squibb & Sons, L.L.C. | 4 | $79 |
| Abbott | 2 | $49 |
| AstraZeneca | 2 | $38 |
| Kestra Medical Technology Services, Inc. | 2 | $35 |
| Bridgebio Pharma, Inc. | 2 | $32 |
| Pfizer | 1 | $30 |
| Biotronik Inc. | 2 | $30 |
| Asahi Intecc USA, Inc. | 1 | $14 |
| Reflow Medical Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Helo Thrombectomy System$1,902
- Peripheral Orbital Atherectomy System$1,717
- CARDIOSAVE HYBRID, TYPE B PLUG$1,200
- AlphaVac$322
- EKOSONIC$291
- Diamondback Coronary$271
- Xcela$249
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$174
- GENERAL VASCULAR INTERVENTION$170
- Impella$146
- KENGREAL$133
- ONYX FRONTIER$101
How this compares
$11,691 in reported general payments places this provider in the 65th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 200 | $228,294 |
| XareltoRivaroxaban | 138 | $141,333 |
| EntrestoSacubitril/Valsartan | 95 | $96,669 |
| Repatha SureclickEvolocumab | 37 | $31,102 |
| FarxigaDapagliflozin Propanediol | 22 | $26,413 |
| Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid | 28 | $13,094 |
| Prasugrel Hcl | 79 | $10,334 |
| Ranolazine ErRanolazine | 50 | $8,734 |
| ClopidogrelClopidogrel Bisulfate | 635 | $7,324 |
| Metoprolol Succinate | 499 | $6,987 |
| Atorvastatin Calcium | 497 | $4,741 |
| Rosuvastatin Calcium | 383 | $3,866 |
| Bisoprolol Fumarate | 139 | $3,657 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 156 | $2,659 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 27 | $2,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $30 | $228,294200 claims |
| Johnson & JohnsonXarelto | $667 | $141,333138 claims |
| NovartisEntresto | $950 | $96,66995 claims |
| AstraZenecaFarxiga | $38 | $26,41322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Atlanta
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Katherine KunkelAtlanta$189K
- James StewartAtlanta$174K
- Pratik SandesaraAtlanta$165K
- Chandanreddy DevireddyAtlanta$121K
- Prashant KaulAtlanta$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.